Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer. Reply
- PMID: 31189049
- DOI: 10.1056/NEJMc1903943
Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer. Reply
Comment on
-
Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer.N Engl J Med. 2019 Jun 13;380(24):2382. doi: 10.1056/NEJMc1903943. N Engl J Med. 2019. PMID: 31189048 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical